Global HPV Testing and Pap Test Market Size Study & Forecast, by Test Type (HPV Testing and Pap Test) and End User (Laboratories, Hospitals, Physician’s Offices & Clinics) and Regional Forecasts 2022-2032

The Global HPV Testing and Pap Test Market is valued approximately at USD 6.28 billion in 2024 and is anticipated to expand at a robust CAGR of 13.20% over the forecast period 2025-2035. HPV testing and Pap tests serve as critical diagnostic tools in the detection and prevention of cervical cancer, enabling timely intervention and improving patient outcomes. HPV testing encompasses Follow-Up HPV Testing, Co-Testing, and Primary HPV Testing, while Pap tests remain a cornerstone of routine cervical screening. The market growth is being propelled by rising awareness of cervical health, increasing prevalence of HPV infections, and substantial investments in diagnostic infrastructure across hospitals, laboratories, and clinics globally. Moreover, the adoption of advanced molecular diagnostic technologies further stimulates the market, offering enhanced sensitivity and accuracy in early detection protocols.

The surging incidence of cervical cancer worldwide has reinforced the indispensable role of HPV testing and Pap tests in preventive healthcare. According to the World Health Organization, cervical cancer remains the fourth most common cancer among women globally, with an estimated 604,000 new cases in 2020. The integration of HPV testing alongside traditional cytology improves diagnostic accuracy, drives early intervention, and enhances patient monitoring. Rising government initiatives promoting cervical cancer screening, coupled with technological innovations such as automated cytology and high-throughput molecular assays, are providing lucrative avenues for market expansion. Nonetheless, challenges including limited access to diagnostic facilities in underdeveloped regions and the growing emphasis on vaccination over screening may modulate growth rates over the forecast period.

Regional dynamics depict North America as the dominant market in 2025, driven by the presence of advanced healthcare infrastructure, extensive screening programs, and widespread adoption of molecular diagnostic solutions. Europe follows closely, fueled by rising healthcare expenditure and proactive national cancer screening initiatives across countries like Germany, the UK, and France. The Asia Pacific region is projected to witness the fastest growth during 2025-2035, propelled by expanding healthcare access, increasing public awareness regarding cervical cancer, and supportive governmental policies in nations such as China, India, and Japan. Latin America and the Middle East & Africa are also expected to register steady growth, with emerging healthcare networks and ongoing investments in diagnostic laboratories providing a positive outlook for market stakeholders.

Major market players included in this report are:
• Roche Diagnostics
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Qiagen N.V.
• Siemens Healthineers
• PerkinElmer, Inc.
• BD Life Sciences
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Fujirebio Inc.
• Cepheid Inc.
• Myriad Genetics, Inc.
• Genomica S.A.U.
• LabCorp

Global HPV Testing and Pap Test Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Test Type:
• HPV Testing (Follow-Up HPV Testing, Co-Testing, Primary HPV Testing)
• Pap Test

By End User:
• Laboratories
• Hospitals
• Physician’s Offices & Clinics

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• RoE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more